Table 4.

Renal excretion parameters in controls, with acetazolamide iv, acetazolamide po, inhaled acetazolamide, methazolamide iv, and N-methyl-acetazolamide iv during normoxia and hypoxia

	n	Normoxia 1 h	Hypoxia 1st h	Hypoxia 2nd h
UV, μl·min−1·kg−1
Series 1
Controls	7	33 ± 24	49 ± 37	32 ± 18
ACZ iv	7	104 ± 28†	123 ± 63†	63 ± 28
ACZ po	7	40 ± 14	76 ± 44	51 ± 28
ACZ inhaled	7	35 ± 23	93 ± 44*	87 ± 41
Series 2
Controls	9	30 ± 26	43 ± 34	25 ± 18
ACZ iv	8	67 ± 31	73 ± 54	68 ± 32
MTZ iv	6	31 ± 28	80 ± 53	74 ± 27
NMA iv	6	42 ± 22	108 ± 76†	53 ± 58
UNAV, μmol·min−1·kg−1
Series 1
Controls	7	0.3 ± 0.3	0.4 ± 0.5	0.8 ± 1.3
ACZ iv	7	5.1 ± 2.1†	5.2 ± 2.0†	6.6 ± 2.5†
ACZ po	7	0.8 ± 0.5	1.3 ± 0.7	1.3 ± 0.5
ACZ inhaled	7	0.4 ± 0.4	7.2 ± 2.8†*	5.1 ± 2.2†*
Series 2
Controls	9	0.2 ± 0.1	0.4 ± 0.4	0.9 ± 1.1
ACZ iv	8	5.6 ± 2.1†	6.6 ± 2.1†	7.9 ± 1.9†*
MTZ iv	6	1.4 ± 0.5	3.5 ± 1.2†	5.3 ± 1.5†*
NMA iv	6	0.5 ± 0.5	1.4 ± 1.1	1.8 ± 1.2
UKV, μmol·min−1·kg−1
Series 1
Controls	7	0.3 ± 0.3	0.4 ± 0.3	0.9 ± 1.4
ACZ iv	7	5.1 ± 3.0†	4.6 ± 2.4†	5.4 ± 3.5†
ACZ po	7	1.8 ± 1.0	2.1 ± 1.2	2.1 ± 1.3
ACZ inhaled	7	0.5 ± 0.4	7.5 ± 2.1†*	5.1 ± 1.5†*
Series 2
Controls	9	0.4 ± 0.5	1.0 ± 1.3	1.9 ± 1.5
ACZ iv	8	5.5 ± 2.6†	5.2 ± 2.0†	5.9 ± 3.0†
MTZ iv	6	4.4 ± 2.4†	4.8 ± 2.1†	5.3 ± 2.1†
NMA iv	6	0.2 ± 0.1	0.6 ± 0.5	0.9 ± 0.7
GFR, ml·min−1·kg−1
Series 1
Controls	7	3.9 ± 0.5	3.8 ± 0.3	3.8 ± 0.5
ACZ iv	7	3.2 ± 0.2	3.1 ± 0.5	3.3 ± 0.6
ACZ po	7	3.0 ± 0.4	3.3 ± 0.6	3.2 ± 0.3
ACZ inhaled	7	3.9 ± 1.0	3.6 ± 0.9	3.6 ± 0.8
Series 2
Controls	9	3.6 ± 0.8	3.8 ± 0.7	3.7 ± 0.7
ACZ iv	8	2.8 ± 0.3	2.9 ± 0.6	3.0 ± 0.6
MTZ iv	6	3.3 ± 0.2	3.3 ± 0.4	3.3 ± 0.5
NMA iv	6	4.1 ± 1.1	3.9 ± 1.1	3.7 ± 0.9

Values are mean ± SD; n, no. of experiments.

UV, urinary volume; U_NAV, urinary sodium excretion; U_KV, urinary potassium excretion; GFR, glomerular filtration rate.

Significant differences (P < 0.05) vs.

^*normoxia and

^†controls at equal time points.